GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology

Neurology

Volumn 79, Issue 19, 2012, Pages 1944-1950

  Tsuang, Debby ^a,b   Leverenz, James B ^a,b   Lopez, Oscar L ^c   Hamilton, Ronald L ^c   Bennett, David A ^d   Schneider, Julie A ^d   Buchman, Aron S ^d   Larson, Eric B ^b,e   Crane, Paul K ^b   Kaye, Jeffrey A ^f   Kramer, Patricia ^f   Woltjer, Randy ^f   Kukull, Walter ^b   Nelson, Peter T ^g   Jicha, Gregory A ^g,h   Neltner, Janna H ^g   Galasko, Doug ⁱ   Masliah, Eliezer ⁱ   Trojanowski, John Q ^j   Schellenberg, Gerard D ^j   Yearout, Dora ^a,b   Huston, Haley ^a,b   Fritts Penniman, Allison ^a,b   Mata, Ignacio F ^a,b   Wan, Jia Y ^b   Edwards, Karen L ^b   Montine, Thomas J ^b   Zabetian, Cyrus P ^a,b   more..

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d RUSH UNIVERSITY   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Departments of Pathology   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GBA PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE NEUROPATHOLOGIC CHANGE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LEWY BODY DISEASE NEUROPATHOLOGIC CHANGE; MALE; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84871226620     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182735e9a     Document Type: Article

References (26)

1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
2. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
3. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67:908-910.
4. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008;65:379-382.
5. Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009;66:578-583.
6. Larson EB, Kukull WA, Teri L, et al. University of Washington Alzheimer's Disease Patient Registry (ADPR): 1987-1988. Aging 1990;2:404-408.
7. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59:1737-1746.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-944.
9. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200-208.
10. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 1994;6:45-58.
11. Leverenz JB, Hamilton R, Tsuang DW, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 2008;18: 220-224.
12. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-210.
13. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
14. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
15. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008;29: 567-583.
16. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005;35:355-364.
17. Mitsui J, Mizuta I, Toyoda A, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009;66:571-576.
18. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82:192-207.
19. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
20. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535.
21. Nelson PT, Schmitt FA, Jicha GA, et al. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol 2010;257:1875-1881.
22. Farrer MJ, Williams LN, Algom AA, et al. Glucosidasebeta variations and Lewy body disorders. Parkinsonism Relat Disord 2009;15:414-416.
23. Nishioka K, Ross OA, Vilarino-Guell C, et al. Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism Relat Disord 2010;17:55-57.
24. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283.
25. Cullen V, Sardi SP, Ng J, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol 2011;69:940-953.
26. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.